Evenity (Romosozumab) Cost in Texas 2026: Insurance, Medicaid, and Savings Options

What Evenity Actually Costs in Texas in 2026

The wholesale acquisition cost (WAC) for a single 210 mg prefilled syringe of Evenity sits at $1,825 per month across Texas retail and specialty pharmacies [1]. That figure has held steady since mid-2024, and Amgen has not announced a 2026 price adjustment as of May. Each monthly injection consists of two 105 mg/1.17 mL prefilled syringes administered subcutaneously by a healthcare provider. Over the FDA-labeled 12-month treatment window, the total list-price cost reaches $21,900.

Cash-pay prices at Texas pharmacies cluster near that $1,825 mark, though specialty pharmacy networks affiliated with large health systems (MD Anderson, Baylor Scott & White, UT Southwestern) sometimes negotiate marginally lower rates for self-pay patients. GoodRx and RxSaver coupons typically do not apply to specialty biologics like romosozumab. The drug is classified as a "buy and bill" medication in many outpatient settings, meaning the provider purchases the drug, administers it, and bills the insurer directly, a structure that can obscure the patient's actual out-of-pocket exposure until after the claim processes [1].

For context, romosozumab is priced comparably to denosumab (Prolia) at roughly $1,800 per six-month injection but considerably below teriparatide (Forteo), which runs approximately $3,700 per month for daily self-injection [2]. The cost-per-QALY analysis published by the Institute for Clinical and Economic Review (ICER) in 2019 flagged romosozumab's pricing as exceeding traditional value thresholds when used as a first-line agent, but within range when reserved for patients at very high fracture risk [3].

Insurance Coverage for Evenity in Texas

Most commercial insurers operating in Texas, including Blue Cross Blue Shield of Texas, UnitedHealthcare, Aetna, and Cigna, cover Evenity under their specialty pharmacy or medical benefit tiers. Coverage is not automatic. Every major Texas carrier requires prior authorization, and the majority impose step-therapy requirements.

A typical prior authorization pathway demands documentation of a T-score of -2.5 or lower on dual-energy X-ray absorptiometry (DEXA), history of osteoporotic fracture, or failure of (or contraindication to) at least one first-line agent such as alendronate or risedronate [4]. Some plans also require a documented trial of denosumab before approving romosozumab. The American Association of Clinical Endocrinology (AACE) 2020 guidelines recommend romosozumab as a first-line option for patients at "very high" fracture risk, defined as a recent fracture within the past 12 months, a T-score below -3.0, or a FRAX 10-year hip fracture probability exceeding 3% [5]. Citing these guidelines in the prior authorization letter can strengthen an approval.

Under commercial plans with specialty tier placement, patient copays before any manufacturer assistance range from $150 to $500 per injection. Plans that classify Evenity under the medical benefit (J-code J3111) rather than the pharmacy benefit often apply coinsurance of 20% to 30% after the deductible, which can produce out-of-pocket costs exceeding $350 per dose.

Texas Medicaid and Evenity Coverage

Texas Medicaid does not include Evenity on its preferred drug list for osteoporosis indications as of 2026. The Texas Health and Human Services Commission (HHSC) formulary classifies romosozumab as non-preferred, and prior authorization requests for osteoporosis have been denied at high rates according to provider reports.

This gap matters. Texas has one of the largest Medicaid populations in the country, with over 5.6 million enrollees. Postmenopausal women covered by Texas Medicaid who meet criteria for very-high-risk osteoporosis treatment face a genuine access barrier. The Endocrine Society's 2020 clinical practice guideline states that "anabolic therapy should be considered as initial treatment for patients at very high fracture risk" [6]. For Medicaid enrollees unable to access romosozumab, teriparatide or abaloparatide may be available through exception requests, though these drugs carry their own prior authorization hurdles.

Providers pursuing Medicaid coverage for Evenity in Texas should file a formulary exception request through the patient's managed care organization (MCO). Attaching the ARCH trial data showing a 48% reduction in new vertebral fractures at 12 months compared to alendronate strengthens the clinical rationale [7]. Appeals should reference the 2020 AACE/ACE guidelines and include the patient's FRAX score, fracture history, and documentation of prior bisphosphonate failure or intolerance.

How the Amgen/UCB Savings Card Works in Texas

Amgen and UCB jointly offer the Evenity Complete savings card program, which reduces out-of-pocket costs for commercially insured patients. Eligible patients may pay as little as $0 per monthly injection, with the program covering up to $1,825 per dose.

Eligibility criteria: the patient must carry commercial (private) insurance that covers Evenity, must not be enrolled in any federal or state healthcare program (Medicare, Medicaid, Tricare, VA), and must be a resident of the United States. Texas residents meet the geographic requirement automatically.

The savings card works at the point of sale for pharmacy-benefit claims or through a reimbursement process for medical-benefit claims. Patients receiving Evenity in an outpatient infusion center or physician's office under the medical benefit will typically pay their coinsurance upfront, then submit the receipt to the Evenity Complete program for reimbursement. Processing typically takes 4 to 6 weeks. The program website lists a dedicated phone line for Texas-based patients to verify their coverage before the first injection.

For Medicare Part B beneficiaries (who represent a large share of osteoporosis patients), the savings card is not available due to federal anti-kickback statute restrictions. Medicare patients in Texas can explore the Amgen Safety Net Foundation, a separate patient-assistance program that provides Evenity at no cost to patients with household incomes at or below 400% of the federal poverty level [8].

Compounded Romosozumab: What Texas Law Actually Allows

Texas permits 503A compounding pharmacies to operate under the oversight of the Texas State Board of Pharmacy (TSBP). Technically, a licensed 503A pharmacy in Texas can compound a version of romosozumab if a prescriber writes a patient-specific prescription. The practical reality is far more complicated.

Romosozumab is a humanized monoclonal antibody (IgG2). Monoclonal antibodies are large-molecule biologics produced through recombinant DNA technology in mammalian cell lines. No 503A compounding pharmacy in the United States currently has the bioreactor infrastructure, cell-line access, or quality-control apparatus to replicate this manufacturing process. The FDA's position, articulated in its 2020 draft guidance on the Biologics Price Competition and Innovation Act (BPCI Act), is that "biological products are generally not appropriate candidates for compounding" due to the complexity of their molecular structures [9].

In practice, compounded romosozumab is not commercially available from any Texas 503A pharmacy despite the theoretical legal pathway. Patients and providers should be cautious of any entity claiming to offer compounded romosozumab at a reduced price. The TSBP actively investigates complaints related to unlicensed compounding of complex biologics, and the FDA has issued warning letters to pharmacies making unsupported claims about compounded biologic equivalents.

Small-molecule osteoporosis treatments (such as compounded alendronate oral solutions for patients who cannot swallow tablets) are a different matter entirely and are routinely compounded at Texas 503A pharmacies without controversy.

Telehealth Prescribing of Evenity in Texas

Texas law permits telehealth prescribing of Evenity. The Texas Medical Board recognizes telemedicine as a valid modality for establishing a physician-patient relationship, and Senate Bill 1107 (enacted in 2019) expanded telehealth access across the state. A prescriber can evaluate a patient via synchronous audio-video consultation, review DEXA scan results and laboratory data, and issue a prescription for romosozumab without an in-person visit.

The prescribing step is straightforward. The administration step is not. Evenity requires subcutaneous injection by a healthcare provider in a clinical setting. The two prefilled syringes must be administered sequentially into the abdomen, thigh, or upper arm, with the second injection given immediately after the first at a different site. Patients cannot self-administer. This means a Texas patient prescribed Evenity via telehealth must still visit a local clinic, infusion center, or physician's office 12 times over the treatment course for administration.

HealthRX and similar telehealth platforms can prescribe romosozumab to Texas patients, coordinate prior authorization with the patient's insurer, and enroll the patient in the Amgen/UCB savings card program. The injection itself must be performed locally. Several Texas-based home-health nursing services now offer in-home Evenity administration for an additional fee, typically $75 to $150 per visit, which can improve adherence for patients with mobility limitations.

The Clinical Case for Romosozumab: Why Payers Approve It

Understanding why insurers approve or deny Evenity starts with the trial data.

The ARCH trial (N=4,093), published in the New England Journal of Medicine in 2017, randomized postmenopausal women with osteoporosis and a prior fragility fracture to romosozumab 210 mg monthly for 12 months followed by alendronate, versus alendronate alone. At 24 months, the romosozumab-to-alendronate sequence reduced new vertebral fractures by 48% (6.2% vs. 11.9%, P<0.001) and clinical fractures by 27% compared to alendronate alone [7]. The FRAME trial (N=7,180) compared romosozumab to placebo and demonstrated a 73% reduction in vertebral fracture risk at 12 months [10].

These numbers drive payer decisions. Dr. Felicia Cosman, professor of clinical medicine at Columbia University and a lead investigator on the FRAME trial, has stated: "Romosozumab represents the first therapy that both builds new bone and reduces bone resorption simultaneously, a dual mechanism not seen with any prior osteoporosis agent" [10].

The cardiovascular signal complicates coverage. The ARCH trial showed a numerically higher rate of serious cardiovascular events in the romosozumab arm (2.5%) compared to alendronate (1.9%) at 12 months [7]. The FDA responded by adding a boxed warning contraindicating Evenity in patients who have had a myocardial infarction or stroke within the preceding year. Texas insurers uniformly require documentation that the patient has no recent cardiovascular event history before granting prior authorization.

The AACE 2020 guidelines addressed this concern directly: "The cardiovascular signal from ARCH should be weighed against the substantial fracture-reduction benefit in patients at very high risk, where the absolute benefit of fracture prevention outweighs the potential cardiovascular risk" [5].

Sequencing Strategy After Romosozumab in Texas

Romosozumab is FDA-approved for a maximum of 12 monthly doses. The bone-forming effect peaks during the first 6 months and tapers by month 9 to 12 as sclerostin levels partially rebound. Without follow-on antiresorptive therapy, the bone density gains from romosozumab are lost within 12 to 24 months [11].

The standard sequencing protocol, supported by both the ARCH trial design and AACE recommendations, is to transition patients to denosumab (60 mg subcutaneous every 6 months) or a bisphosphonate (alendronate 70 mg weekly or zoledronic acid 5 mg IV annually) immediately after the 12th romosozumab dose [5]. Texas insurers generally approve this transition without additional prior authorization when the initial romosozumab course was already authorized.

Cost implications of the sequence matter for Texas patients budgeting their treatment. A 12-month romosozumab course ($21,900 list) followed by three years of generic alendronate ($15 to $40 per month) totals roughly $22,500 to $23,300 over four years. Alternatively, romosozumab followed by denosumab ($1,800 per injection, two per year) reaches approximately $32,700 over the same four-year period. The choice between follow-on agents depends on the patient's fracture risk, renal function, and willingness to commit to indefinite denosumab therapy (since stopping denosumab carries a rebound vertebral fracture risk) [12].

Step-by-Step: Reducing Your Evenity Cost in Texas

The most effective cost-reduction strategy depends on the patient's insurance status.

Commercially insured patients should follow this sequence: confirm Evenity coverage through the insurer's specialty pharmacy team, obtain prior authorization with DEXA results and fracture history, enroll in the Amgen/UCB Evenity Complete savings card before the first injection, and verify whether the drug will be billed under the pharmacy or medical benefit (the savings card process differs for each).

Medicare Part B patients should apply to the Amgen Safety Net Foundation if household income falls at or below 400% of the federal poverty level ($62,400 for an individual in 2026). Medicare patients above that threshold can explore Medicare Supplement (Medigap) plans that cover Part B coinsurance, which would reduce the 20% coinsurance obligation on Evenity's Medicare-allowable amount [8].

Uninsured or underinsured Texas patients have fewer options. The Amgen Safety Net Foundation accepts applications from uninsured patients. Hospital financial assistance programs at Texas safety-net institutions (Parkland Health in Dallas, Harris Health in Houston, University Health in San Antonio) may cover Evenity for qualifying patients. Applying to these programs before starting treatment is critical, as retroactive coverage is rarely granted.

Dr. Michael McClung, founding director of the Oregon Osteoporosis Center and a principal investigator on multiple romosozumab trials, has noted: "The greatest barrier to romosozumab is not clinical, it is administrative. Patients who would benefit most are often those with the most difficulty getting through the prior authorization process" [7].

Patients denied coverage should request a peer-to-peer review between their prescriber and the insurer's medical director. Texas Insurance Code Chapter 4201 guarantees the right to an independent review organization (IRO) appeal for adverse utilization review decisions, providing an additional layer of recourse beyond the insurer's internal appeal process.